What's happened
A roundup of recent cancer breakthroughs highlights new immunotherapies, targeted drugs and surgical-sparing treatments. The Independent reports on Scolyer’s pioneering work and a landmark NICE decision; The Guardian covers durvalumab’s promise in bladder cancer; Business Insider UK and Reuters summarize ASCO findings on pancreatic and colon cancers, among others.
What's behind the headline?
Key Themes
- Targeted therapies are expanding options for patients with specific mutations (e.g., Ras variants, EGFR insertions), potentially extending survival and enabling life with cancer.
- Immunotherapy is increasingly deployed to reduce the need for invasive surgeries (e.g., bladder-sparing approaches) and to enhance treatment efficacy across tumor types.
- Genetic profiling and biomarker-driven trials are becoming standard, guiding who benefits from new drugs.
What this means for readers
- Treatments are becoming more personalized and less disruptive to daily life.
- Access to cutting-edge therapies is expanding in some health systems, but costs and equity remain critical questions.
- The pace of innovation means patients and families should seek up-to-date information from clinicians and trusted sources.
How we got here
The articles reflect a wave of developments showcased at ASCO 2026, including immunotherapies, targeted therapies and less invasive approaches across several cancer types. Key themes include slowing progression, extending survival, and preserving organ function, with clinical trials expanding genetic screening and personalized treatment.
Our analysis
The Independent, The Guardian, Business Insider UK, Reuters were used to illustrate advances across multiple cancer types and treatment modalities. Direct quotes and attributions are provided within those articles.
Go deeper
- What new therapy is most likely to change patient care in the next year?
- How can patients access emerging treatments through trials or approved programs?
- What biomarkers guide these new therapies and how widely are they tested?
More on these topics
-
American Society of Clinical Oncology - Organization
The American Society of Clinical Oncology is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer.
-
Chicago - City in Illinois
Chicago, officially the City of Chicago, is the most populous city in the U.S. state of Illinois, and the third-most-populous city in the United States.
-
Cancer Research UK - Corporation
Cancer Research UK is a cancer research and awareness charity in the United Kingdom and Isle of Man, formed on 4 February 2002 by the merger of The Cancer Research Campaign and the Imperial Cancer Research Fund.